This phase I trial is evaluating the combination of an oral therapy (olaparib) and a combination therapy (177Lu-PSMA) in patients with castration resistant prostate cancer that has spread to other parts of the body and progressed on other targeted treatments.
This trial is treating patients with castration resistant prostate cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer
Other Non-Commercial Sponsor
Peter MacCallum Cancer Centre
To be eligible for this trial, patients must have metastatic castration resistant prostate cancer (mCRPC) that has progressed with a novel AR targeted agent (abiraterone and/or enzalutamide and/or apalutamide) and has not previously been exposed to platinums, PARP inhibitors or 177Lu-PSMA. Patients can have had prior exposure to docetaxel in the chemotherapy naïve setting or castrate setting. Eligible patients will be enrolled in the trial in two stages: a dose escalation and expansion stage. Depending on the stage of enrolment, patients will receive either escalating or fixed 7.4 GBq of 177Lu-PSMA every 6 weeks together with olaparib on days 2-15 of each cycle. A cycle is 42 days long. Patients will receive up to 4 cycles of treatment.
Recruiting Hospitals Read More